The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

Eli Lilly is paying up to $630m for a Phase I metabolic-associated ... the candidate is also in preclinical development for ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

Lilly's retatrutide shows remarkable weight loss in trials but raises concerns with side effects possibly linked to the drug like nausea and kidney stones. Read more here.

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...

Byline: Hank Popeil In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ingenuity but for their potential to radically improve human ...

These drugs belong to a class known as glucagon-like peptide receptor agonists (GLP-1RAs), which mimic a natural hormone that ...

As India awaits the launch of obesity drug, Mounjaro, the debate on weight loss drugs and body image continues ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...